Variation within voltage-gated calcium channel genes and antipsychotic treatment response in a South African first episode schizophrenia cohort

The Pharmacogenomics Journal
Kevin S O'ConnellLouise Warnich

Abstract

Voltage-gated calcium channels have been implicated in schizophrenia aetiology; however, little is known about their involvement in antipsychotic treatment response. This study investigated variants within the calcium channel subunit genes for association with antipsychotic treatment response in a first episode schizophrenia cohort. Twelve regulatory variants within seven genes were shown to be significantly associated with treatment outcome. Most notably, the CACNA1B rs2229949 CC genotype was associated with improved negative symptomology, where the C allele was predicted to abolish a miRNA-binding site (has-mir-5002-3p), suggesting a possible mechanism of action through which this variant may have an effect. These results implicate the calcium channel subunits in antipsychotic treatment response and suggest that increased activation of these channels may be explored to enhance or predict antipsychotic treatment outcome.

References

Jul 1, 1991·Pharmacology, Biochemistry, and Behavior·R L SuddathR J Wyatt
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Dec 1, 1996·Journal of Clinical Psychopharmacology·K YamadaM Asai
Dec 31, 2005·Nucleic Acids Research·David S WishartJennifer Woolsey
Aug 30, 2008·Neuropsychiatric Disease and Treatment·Antonio GambardellaAldo Quattrone
May 1, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Julia E Sommer, Elaine C Budreck
Jul 25, 2009·Proceedings of the National Academy of Sciences of the United States of America·Michael E CahillPeter Penzes
Aug 4, 2009·Genome Research·David H AlexanderKenneth Lange
Nov 26, 2009·Bioinformatics·Eric R GamazonNancy J Cox
Apr 1, 2010·Nature Methods·Ivan A AdzhubeiShamil R Sunyaev
Jan 18, 2011·Molecular and Cellular Neurosciences·Devi MajumdarDonna J Webb
Sep 20, 2011·Nature Genetics·UNKNOWN Psychiatric GWAS Consortium Bipolar Disorder Working Group
Dec 16, 2011·Bioinformatics·Kai XiaFred A Wright
Jun 19, 2012·Progress in Neurobiology·Shambhu BhatTodd D Gould
Aug 31, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yu-bin WangJian-hong Luo
Sep 8, 2012·Genome Research·Alan P BoyleMichael Snyder
Oct 3, 2012·Handbook of Experimental Pharmacology·Richard S E Keefe, Philip D Harvey
Mar 5, 2013·Lancet·UNKNOWN Cross-Disorder Group of the Psychiatric Genomics Consortium
May 15, 2013·Journal of Psychiatric Research·Tayfun UzbaySelcuk Kirli
May 30, 2013·Nature Genetics·UNKNOWN GTEx Consortium
Jul 25, 2013·European Archives of Psychiatry and Clinical Neuroscience·Claudia WolfOliver Gruber
Nov 29, 2013·Nucleic Acids Research·Liyuan GuoJing Wang
Jul 25, 2014·Nature·UNKNOWN Schizophrenia Working Group of the Psychiatric Genomics Consortium
Mar 12, 2015·Human Psychopharmacology·Bonginkosi ChilizaRobin Emsley
Aug 13, 2015·ELife·Vikram AgarwalDavid P Bartel
Sep 20, 2015·Progress in Neurobiology·Samuel HeyesAnnette C Dolphin

❮ Previous
Next ❯

Citations

Jul 25, 2019·International Journal of Molecular Sciences·Arturo AndradeLaura Londrigan

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

ADMIXTURE
regulomeDB
SIFT
Nexus
SNP
lmerTest
R
polymiRTS
rSNPBase
PolyPhen

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here